MY124078A - Eletriptan hydrobromide monohydrate - Google Patents

Eletriptan hydrobromide monohydrate

Info

Publication number
MY124078A
MY124078A MYPI99005153A MYPI9905153A MY124078A MY 124078 A MY124078 A MY 124078A MY PI99005153 A MYPI99005153 A MY PI99005153A MY PI9905153 A MYPI9905153 A MY PI9905153A MY 124078 A MY124078 A MY 124078A
Authority
MY
Malaysia
Prior art keywords
eletriptan hydrobromide
hydrobromide monohydrate
monohydrate
eletriptan
preparing
Prior art date
Application number
MYPI99005153A
Inventor
Christopher Ian Dallam
Ronald James Ogilvie
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MY124078A publication Critical patent/MY124078A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Electroluminescent Light Sources (AREA)
  • Lasers (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

THE PRESENT INVENTION PROVIDES ELETRIPTAN HYDROBROMIDE MONOHYDRATE OF THE FORMULA (I):TOGETHER WITH PROCESSES FOR PREPARING,USES OF, AND COMPOSITIONS CONTAINING,SAID MONOHYDRATE.
MYPI99005153A 1998-11-27 1999-11-25 Eletriptan hydrobromide monohydrate MY124078A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9825988.0A GB9825988D0 (en) 1998-11-27 1998-11-27 Indole derivatives

Publications (1)

Publication Number Publication Date
MY124078A true MY124078A (en) 2006-06-30

Family

ID=10843140

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI99005153A MY124078A (en) 1998-11-27 1999-11-25 Eletriptan hydrobromide monohydrate

Country Status (53)

Country Link
US (2) US20020013358A1 (en)
EP (1) EP1135381B1 (en)
JP (1) JP3777094B2 (en)
KR (1) KR100413739B1 (en)
CN (1) CN1131860C (en)
AP (1) AP2001002149A0 (en)
AR (1) AR024232A1 (en)
AT (1) ATE273300T1 (en)
AU (1) AU754731B2 (en)
BG (1) BG64706B1 (en)
BR (1) BR9915692A (en)
CA (1) CA2352392C (en)
CO (1) CO5150178A1 (en)
CR (1) CR6325A (en)
CU (1) CU23269A3 (en)
CZ (1) CZ295472B6 (en)
DE (1) DE69919388T2 (en)
DK (1) DK1135381T3 (en)
DZ (1) DZ2948A1 (en)
EA (1) EA003551B1 (en)
EE (1) EE04914B1 (en)
ES (1) ES2224701T3 (en)
GB (1) GB9825988D0 (en)
GC (1) GC0000113A (en)
GE (1) GEP20043183B (en)
GT (1) GT199900202A (en)
HK (1) HK1042898B (en)
HN (1) HN1999000196A (en)
HR (1) HRP20010398B1 (en)
HU (1) HUP0105308A3 (en)
ID (1) ID28802A (en)
IL (1) IL141663A (en)
IS (1) IS2238B (en)
MA (1) MA26708A1 (en)
MY (1) MY124078A (en)
NO (1) NO320798B1 (en)
NZ (1) NZ510055A (en)
OA (1) OA11671A (en)
PA (1) PA8485701A1 (en)
PE (1) PE20001299A1 (en)
PL (1) PL194503B1 (en)
PT (1) PT1135381E (en)
RS (1) RS50002B (en)
SI (1) SI1135381T1 (en)
SK (1) SK285774B6 (en)
SV (1) SV1999000204A (en)
TN (1) TNSN99221A1 (en)
TR (1) TR200101493T2 (en)
TW (1) TWI246512B (en)
UA (1) UA68402C2 (en)
UY (2) UY25823A1 (en)
WO (1) WO2000032589A1 (en)
ZA (1) ZA200102681B (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0018968D0 (en) * 2000-08-02 2000-09-20 Pfizer Ltd Particulate composition
MXPA05010070A (en) 2003-04-11 2005-11-23 Pfizer Pharmaceutical combination comprising eletriptan and sodium bicarbonate.
US6927296B2 (en) 2003-07-23 2005-08-09 Pfizer Inc. Process
GB0317229D0 (en) * 2003-07-23 2003-08-27 Pfizer Ltd Improved process
US20080287519A1 (en) * 2007-05-01 2008-11-20 Marioara Mendelovici Amorphous eletriptan hydrobromide and process for preparing it and other forms of eletriptan hydrobromide
US20080319205A1 (en) * 2007-05-29 2008-12-25 Roman Bednar Process for preparing 5-bromo-3-[(R)-1-methyl-pyrrolidin-2-ylmethyl]-1H-indole
US20100285075A1 (en) * 2007-12-17 2010-11-11 Actavis Group Ptc Ehf Novel Hemioxalate Salt of Eletriptan
WO2010097703A1 (en) * 2009-02-25 2010-09-02 Actavis Group Ptc Ehf Highly pure eletriptan or a pharmaceutically acceptable salt thereof substantially free of eletriptan n-oxide impurity
WO2010116386A2 (en) * 2009-04-08 2010-10-14 Biophore India Pharmaceuticals Pvt. Ltd. Novel polymorph of eletriptan hydrobromide and process for the preparation thereof
WO2011089614A1 (en) * 2010-01-19 2011-07-28 Sms Pharmaceuticals Limited PROCESS FOR PREPARING ELETRIPTAN HYDROBROMIDE HAVING α-FORM
WO2014063752A1 (en) 2012-10-26 2014-05-01 Synthon Bv Process for making crystalline form alpha of eletriptan hydrobromide
CN103893112A (en) * 2012-12-31 2014-07-02 重庆圣华曦药业股份有限公司 Eletriptan hydrobromide injection
CN107954947A (en) * 2016-10-14 2018-04-24 北京莱瑞森医药科技有限公司 Vortioxetine hydrobromate crystal form C and preparation method thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3952741A (en) 1975-01-09 1976-04-27 Bend Research Inc. Controlled release delivery system by an osmotic bursting mechanism
FR2624732B1 (en) 1987-12-21 1991-02-15 Synthelabo SUSTAINED RELEASE PHARMACEUTICAL FORMULATION
US5474784A (en) 1990-03-02 1995-12-12 British Technology Group Limited Dispensing device
HUT64326A (en) 1990-10-15 1993-12-28 Pfizer Process for production indole derivatives and pharmaceutical preparations containing these compounds
US5545644A (en) * 1990-10-15 1996-08-13 Pfizer Inc. Indole derivatives
US5464633A (en) 1994-05-24 1995-11-07 Jagotec Ag Pharmaceutical tablets releasing the active substance after a definite period of time
GB9417310D0 (en) * 1994-08-27 1994-10-19 Pfizer Ltd Therapeutic agents
GB9510223D0 (en) 1995-05-20 1995-07-19 Pfizer Ltd Therapeutic agent
TW448172B (en) * 1996-03-08 2001-08-01 Pharmacia & Upjohn Co Llc Novel hydroxamic acid derivatives useful for the treatment of diseases related to connective tissue degradation
US5998462A (en) * 1996-12-16 1999-12-07 Allelix Biopharmaceuticals Inc. 5-alkyl indole compounds
GB9704498D0 (en) * 1997-03-05 1997-04-23 Glaxo Wellcome Spa Chemical compound
ATE206921T1 (en) 1997-07-03 2001-11-15 Pfizer PHARMACEUTICAL COMPOSITIONS CONTAINING ELETRIPTANHEMISULFATE AND CAFFEINE

Also Published As

Publication number Publication date
CN1131860C (en) 2003-12-24
AU754731B2 (en) 2002-11-21
SI1135381T1 (en) 2004-10-31
CO5150178A1 (en) 2002-04-29
WO2000032589A1 (en) 2000-06-08
CA2352392A1 (en) 2000-06-08
SK6992001A3 (en) 2002-01-07
SV1999000204A (en) 2000-10-16
HUP0105308A3 (en) 2003-01-28
SK285774B6 (en) 2007-08-02
NO20012584L (en) 2001-07-27
BR9915692A (en) 2001-08-14
EA200100297A1 (en) 2001-08-27
NO320798B1 (en) 2006-01-30
KR100413739B1 (en) 2004-01-03
US7238723B2 (en) 2007-07-03
RS50002B (en) 2008-09-29
HRP20010398B1 (en) 2004-12-31
UA68402C2 (en) 2004-08-16
UY25823A1 (en) 2001-08-27
ES2224701T3 (en) 2005-03-01
AP2001002149A0 (en) 2001-06-30
TNSN99221A1 (en) 2005-11-10
PL194503B1 (en) 2007-06-29
EE200100285A (en) 2002-08-15
CN1328554A (en) 2001-12-26
JP3777094B2 (en) 2006-05-24
PT1135381E (en) 2004-10-29
AR024232A1 (en) 2002-09-25
BG105539A (en) 2001-12-29
GB9825988D0 (en) 1999-01-20
DE69919388T2 (en) 2005-09-29
YU18801A (en) 2003-07-07
NZ510055A (en) 2004-11-26
MA26708A1 (en) 2004-12-20
US20050131237A1 (en) 2005-06-16
CA2352392C (en) 2006-01-24
CU23269A3 (en) 2008-04-09
BG64706B1 (en) 2005-12-30
DE69919388D1 (en) 2004-09-16
NO20012584D0 (en) 2001-05-25
IL141663A0 (en) 2002-03-10
CZ295472B6 (en) 2005-08-17
DK1135381T3 (en) 2004-11-15
JP2002531449A (en) 2002-09-24
HK1042898A1 (en) 2002-08-30
DZ2948A1 (en) 2004-03-15
PE20001299A1 (en) 2000-12-01
ID28802A (en) 2001-07-05
EP1135381A1 (en) 2001-09-26
GEP20043183B (en) 2004-02-25
HRP20010398A2 (en) 2002-06-30
HN1999000196A (en) 2005-11-26
OA11671A (en) 2005-01-12
KR20010080594A (en) 2001-08-22
AU6225399A (en) 2000-06-19
PA8485701A1 (en) 2000-09-29
IS2238B (en) 2007-05-15
ZA200102681B (en) 2002-07-02
EA003551B1 (en) 2003-06-26
CR6325A (en) 2008-07-02
UY25825A1 (en) 2000-08-21
PL347928A1 (en) 2002-04-22
CZ20011839A3 (en) 2001-10-17
TR200101493T2 (en) 2002-02-21
IL141663A (en) 2004-05-12
TWI246512B (en) 2006-01-01
HUP0105308A2 (en) 2002-05-29
EE04914B1 (en) 2007-10-15
EP1135381B1 (en) 2004-08-11
GC0000113A (en) 2005-06-29
IS5868A (en) 2001-02-27
GT199900202A (en) 2001-05-19
ATE273300T1 (en) 2004-08-15
HK1042898B (en) 2004-10-08
US20020013358A1 (en) 2002-01-31

Similar Documents

Publication Publication Date Title
AP9901534A0 (en) Pharmaceutical formulations.
DE60112609D1 (en) Pyrazolopyridine
DE60112974D1 (en) Carbolinderivate
MY134559A (en) Lactam compound to inhibit beta-amyloid peptide release or synthesis
HK1047887A1 (en) Use of thiazolidin- or pyrrolidin-derivatives of aminoacids as antihyperglycemic agents.
MXPA03011197A (en) Benzoylsulfonamides and sulfonylbenzamidines for use as antitumour agents.
GB9514473D0 (en) Chemical compounds
UA34466C2 (en) Agent for non-systemic control of parasites
MXPA04004939A (en) 3-alkylated-5,5',6,6',7,7',8,8'-octahydro-2,2'-binaphthols and 3,3'-dialkylated-5,5',6,6',7,7',8,8'-octahydro-2,2'-binaphthols and processes for making them.
DE60112330D1 (en) Pyrazolopyridinderivate
DE60216233D1 (en) Carbolinderivate
HRP20020330B1 (en)
MXPA03002911A (en) Chemical compounds.
MXPA02012076A (en) Chemical compounds.
AU2001266575A1 (en) Chemical compounds
MY124078A (en) Eletriptan hydrobromide monohydrate
DE60201074D1 (en) Pyrazolopyridinderivate
EP1073447A4 (en) N1-modified glycopeptides
AP2001002045A0 (en) FKBP inhibitors.
MXPA02012472A (en) Chemical compounds.
PL340459A1 (en) Agonists of 5ht1f
ATE282608T1 (en) QUINOXALINDIONES
PL343546A1 (en) Processes for preparing intermediates
ZA200110213B (en) The use of the protein UK 114 for inhibiting organ transplant rejection.
TWI231815B (en) Glycopeptide derivatives and pharmaceutical compositions containing the same for use as antibacterial agents